Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Equity Average (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Equity Average for 6 consecutive years, with $133.6 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 43.17% to $133.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $133.6 million through Dec 2025, down 43.17% year-over-year, with the annual reading at $182.0 million for FY2025, 7.08% down from the prior year.
  • Equity Average for Q4 2025 was $133.6 million at TScan Therapeutics, down from $160.4 million in the prior quarter.
  • The five-year high for Equity Average was $242.2 million in Q3 2024, with the low at -$55.0 million in Q2 2021.
  • Average Equity Average over 5 years is $136.3 million, with a median of $146.0 million recorded in 2022.
  • The sharpest move saw Equity Average soared 533.15% in 2021, then plummeted 43.17% in 2025.
  • Over 5 years, Equity Average stood at $167.4 million in 2021, then plummeted by 35.47% to $108.0 million in 2022, then soared by 48.01% to $159.9 million in 2023, then surged by 46.97% to $235.0 million in 2024, then tumbled by 43.17% to $133.6 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $133.6 million, $160.4 million, and $193.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.